Posted on

cbd oil cures lung cancer

The National Institutes of Health has prepared a PDQ document (FAQs) on the topic of Cannabis and Cannabinoids. As is true when taking anything along with prescribed medications, be sure to talk to your doctor before taking CBD in any form.

The Hope With Answersâ„  Intro video series discusses the use of CBD oil for lung cancer. Dr. Ross Camidge of the University of Colorado Medical Center and Matt Arensdorff, lung cancer patient advocate. provides basic information for those newly diagnosed with lung cancer. Start your journey of understanding and learn more about the importance of detecting lung cancer early and methods for detection and treatment.

Learn about CBD oil, THC, and Marijuana and their uses for lung cancer patients through this discussion between Dr. Ross Camidge of the University of Colorado Medical Center and Matt Arensdorf, lung cancer patient and advocate:

Hope With Answers Video Series: CBD and Lung Cancer

More detailed information is shared in this intermediate video from Hope with Answers, providing more details for those who need a deeper knowledge about issues surrounding lung cancer. In this video, Dr. Ross Camidge along with patient and advocate Matt Aresndorf dig a little deeper answering questions like “Can CBD oil be used to help lung cancer patients?” and “What can it be used for?”

It has been described that CBD can act on tumour cells, directly or indirectly, through different pathways and that these effects might vary in different tumour cells. CBD acts as an inverse agonist for CB2 receptor and an antagonist for CB1 receptor. 12 However, CBD has low affinity to either CB1 or CB2 receptors. 9 In addition, CBD has anti-cancer effects acting as an agonist for the transient receptor potential vanilloid (TRPV) 1 and 2 leading to changes in intracellular Ca 2+ levels. 5,13

It is also reported that CBD can induce apoptosis in cancer cells via the production of reactive oxygen species (ROS), caspase activation 4,13,14 and activation of p53 dependent apoptotic pathways in cancer cells 14,15 and down-regulation of mammalian target of rapamycin (mTOR) and cyclin D1. 16 CBD can also upregulate TNF/TNFR1 and TRAIL/TRAIL-R2 signalling by modulation of both ligand and receptor levels followed by apoptosis. 14 Furthermore, CBD inhibits human umbilical vein endothelial cells (HUVEC) endothelial cells migration, invasion and sprouting in vitro, and angiogenesis in vivo through down-modulation of several angiogenesis-related molecules. 17

A CT scan in December 2016 showed that the lung mass had increased in size to 2.7 × 2.8 cm though the mediastinal and left hilar lymph nodes had not changed in size. The patient was offered treatment but again declined. A chest X-ray in July 2017 showed progressive changes in the left lower zone but no significant collapse or effusion evident. The patient had a further CT scan in November 2017 which revealed near total resolution of the left lower lobe mass with only a small area of residual spiculated soft tissue remaining (1.3 × 0.6 cm) and a significant reduction in size and number of mediastinal lymph nodes ( Figure 2(a) and ( ​ (b)). b )). The patient underwent another CT scan in January 2018 which showed stable appearances of the small residual opacity in the left lower lobe and mediastinal lymph nodes.

Discussion

The challenge to improve the outcome of patients with lung cancer is leading to the evaluation of alternative drugs which, alone or in combination, may lead to improved response and survival in patients with lung cancer. Therefore, further development of new drugs or even established therapies previously used to treat non-malignant diseases (drug repurposing) which could have shown an effect on lung cancer in vitro and/or in vivo are worth pursuing.

Funding: The author(s) received no financial support for the research, authorship, and/or publication of this article.

The patient was offered chemotherapy and radiotherapy, but he declined as he was in his 80s and did not want any treatment that could adversely affect his quality of life. The decision was made to follow the patient up but without active treatment.

The data presented here may indicate that CBD led to a partial tumour response in a patient with histologically proven adenocarcinoma of the lung. Various possible mechanisms of action leading to this objective response might be postulated.